Molecular Templates Inc

NASDAQ:MTEM  
7.85
-0.49 (-5.88%)
Products

Molecular Templates, Inc. Provides Update On MT-5111 Phase 1 Study

Published: 12/21/2020 23:26 GMT
Molecular Templates Inc (MTEM) - Molecular Templates, Inc. Provides Update on Mt-5111 Phase 1 Study.
Molecular Templates Inc - Phase 1 Study Dose Escalation Ongoing in All Her2 Positive Tumor Types.
Molecular Templates Inc - Her2 Positive Breast Cancer Expansion Cohort Planned to Be Initiated in 1h21.
Molecular Templates Inc - Expansion Cohorts in Additional Tumors Types to Begin When Mtd Or Recommended Phase 2 Dose is Reached.
Molecular Templates Inc - Mt5111 Appears to Be Well Tolerated With No Dose Limiting Toxicities (dlts) Observed in Any Cohort.
Molecular Templates Inc - Expect to Provide an Update on Results From Subject Currently on Treatment in 1h21.
Molecular Templates Inc - Expect to Provide an Update on Results From Higher Dose Cohorts From Dose Escalation Portion of Phase 1 Study in 1h21.